Copaxone Reduces Its Dosing Schedule, But Can It Shrink The Competition?
This article was originally published in The Pink Sheet Daily
Wall Street is mixed on whether Teva’s newly approved three-times-weekly formulation will protect its MS blockbuster franchise.
You may also be interested in...
Sandoz/Momenta’s Glatopa (glatiramer) met four criteria for equivalence that ‘provide overlapping and confirmatory evidence of active ingredient sameness,’ FDA says.
With the imminent possibility of generic competition to Copaxone, Teva looks to move 65% of current patients to its thrice-weekly version by the end of 2014.
The company will focus its R&D resources on central nervous system disorders and respiratory disease, but will end investment in women’s health and oncology.